Company intelligence / Profile preview

Zhongmou Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

Zhongmou Therapeutics is developing optogenetic gene therapies delivered via AAV vectors for degenerative retinal diseases. Their approach aims to restore vision by enabling retinal cells to respond to light, independent of the underlying genetic mutation. Lead candidates are in early phase clinical trials targeting retinitis pigmentosa, retinoschisis, and cone rod dystrophy. No published late-stage or pivotal results as of May 2025.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (AAV vector-based)Optogenetics
Industry: Biotech

Drug pipeline

6 assets

ZM-01-L

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Zhongmou Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhongmou Therapeutics.

Explore the full profile